Based on the CASPIAN and IMpower133 trials, two PD-L1 inhibitors, duvalumab and atezolizumab, combined with chemotherapy, have been recommended as the new standard first-line treatment of ES-SCLC by the guidelines [4, 5]. This evidence concerns the gene CD274 and small cell lung carcinoma.